CGIM
ACRS icon

Cannon Global Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Cannon Global Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,400
Closed -$57.2K – 70
2025
Q1 		$57.2K Buy
+37,400
New +$79.8K 0.1% 76

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannon Global Investment Management's ACRS Position: Q2 2025 in Review

Cannon Global Investment Management sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 37,400 shares — an estimated $57.2K sold.

Cannon Global Investment Management first reported a position in ACRS in Q1 2025 and held it in 1 quarter. The position peaked at $57.2K in Q1 2025. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Cannon Global Investment Management reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 37,400 Aclaris Therapeutics shares in Q2 2025, an estimated $57.2K.
  • Cannon Global Investment Management first reported a position in Aclaris Therapeutics in Q1 2025 and held it in 1 quarter.
  • Cannon Global Investment Management's Aclaris Therapeutics position peaked at $57.2K in Q1 2025.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Cannon Global Investment Management's 13F filing for Q2 2025, filed 29 Jul 2025.